SPERO THERAPEUTICS INC's ticker is SPRO and the CUSIP is 84833T103. A total of 90 filers reported holding SPERO THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $986,000 | -83.7% | 113,322 | -70.1% | 0.02% | -80.8% |
Q4 2021 | $6,067,000 | -40.7% | 378,932 | -31.8% | 0.12% | -35.6% |
Q3 2021 | $10,229,000 | +120.3% | 555,614 | +67.0% | 0.19% | +123.0% |
Q2 2021 | $4,644,000 | -7.8% | 332,639 | -2.8% | 0.09% | -18.7% |
Q1 2021 | $5,036,000 | -38.2% | 342,113 | -18.6% | 0.11% | -41.5% |
Q4 2020 | $8,150,000 | +95.2% | 420,320 | +12.4% | 0.18% | +28.9% |
Q3 2020 | $4,175,000 | +85.2% | 374,078 | +124.5% | 0.14% | +75.3% |
Q2 2020 | $2,254,000 | +62.7% | 166,606 | -2.8% | 0.08% | +8.0% |
Q1 2020 | $1,385,000 | -3.2% | 171,434 | +15.2% | 0.08% | +13.6% |
Q4 2019 | $1,431,000 | -8.5% | 148,867 | +0.9% | 0.07% | -23.3% |
Q3 2019 | $1,564,000 | -1.8% | 147,543 | +6.7% | 0.09% | +8.9% |
Q2 2019 | $1,592,000 | -11.6% | 138,295 | -1.6% | 0.08% | -18.6% |
Q1 2019 | $1,800,000 | +89.7% | 140,526 | -8.9% | 0.10% | +44.8% |
Q4 2018 | $949,000 | -42.5% | 154,306 | -1.8% | 0.07% | -25.6% |
Q3 2018 | $1,651,000 | -25.5% | 157,058 | +3.9% | 0.09% | -32.8% |
Q2 2018 | $2,217,000 | – | 151,148 | – | 0.13% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Atlas Venture Associates IX, LLC | 1,376,968 | $2,754,000 | 8.16% |
Aquilo Capital Management, LLC | 3,403,210 | $6,806,000 | 2.45% |
OUP Management Co., LLC | 249,070 | $498,000 | 0.78% |
AWM Investment Company, Inc. | 2,300,400 | $4,601,000 | 0.70% |
Murchinson Ltd. | 762,700 | $1,525,000 | 0.44% |
Anson Funds Management LP | 1,473,872 | $2,948,000 | 0.35% |
Atlas Venture Life Science Advisors, LLC | 1,031,160 | $2,062,000 | 0.23% |
BVF INC/IL | 1,929,376 | $3,859,000 | 0.16% |
Oasis Management Co Ltd. | 288,000 | $576,000 | 0.10% |
Alphabet Inc. | 889,979 | $1,780,000 | 0.09% |